Leveraging advanced Data and AI solutions, improves patient engagement, and strengthens the value proposition of drug and vaccine treatments.
Data Driven Demonstration
In today’s competitive pharmaceutical landscape, demonstrating the value of drug and vaccine treatments requires more than traditional methods—it demands robust, data-driven intelligence that informs strategic decisions and builds stakeholder confidence.
OpenSky leverages the power of Microsoft Fabric, advanced data science, and augmented analytics to uncover actionable insights that drive market access and patient activation.
How it Works
Our platform integrates anonymised data from diverse sources, including:
Demographics: Understand patient populations and tailor engagement strategies.
Treatment Status: Track uptake, adherence, and outcomes.
Socio-Economic Indicators: Identify barriers to access and target interventions effectively.
Healthcare System Statistics: Align market strategies with system capacity and trends.
By combining this data into a unified model, pharmaceutical companies can:
Strengthen Value Propositions
Use real-world evidence to showcase the effectiveness and societal impact of treatments to payers, policymakers, and healthcare providers.
Enhance Market Access Strategies
Predict outcomes and optimise investments in engagement, advocacy, and coalition building.
Improve Commercial Decision Making
Deploy predictive models that forecast ROI for marketing campaigns and stakeholder engagement initiatives.
Introducing VaxLens Service
From Data to Narrative:
A dedicated service to pharmaceutical policy teams that supports strategies to maximise vaccine market access, by defining and demonstrating vaccine value.
VaxLens Service by OpenSky is our bespoke service specifically developed for the pharmaceutical sector. VaxLens represents a paradigm shift in vaccine management and distribution, offering unparalleled insights and operational control.
Learn more about how VaxLens can transform your vaccine lifecycle management
Success Spotlight - VaxLens in Action at MSD Pharmaceuticals
VaxLens has already paved the way for groundbreaking advancements in the industry.
At MSD Pharmaceuticals, our collaboration has led to:
Enhanced vaccine distribution efficiency.
Improved inventory management.
Real-time data insights for better decision-making.
About the Research & the Report
MSD commissioned OpenSky to conduct and complete a Research report which would outline the correlation between the existence of evolved EVRs (Electronic Vaccination Registries) and higher Vaccine Coverage Rates (VCRs) in the EU, the UK, Norway, Switzerland and Serbia.
Using the HPV Vaccination as a case study, the research commenced in November 2021 and continued into Q2 2022, capturing in-depth data from every country and delivering a heatmap & scoreboard to visualise the correlation between EVRs and VCRs.
.png?width=200&height=200&name=VaxLens%20Logo%20(1).png "VaxLens Logo (1)")
